Answers are grounded in this paper and cite their sources.
Periodontitis is a globally prevalent chronic inflammatory disease strongly associated with specific periodontal pathogens, particularly Porphyromonas gingivalis (P. gingivalis), which plays a major role in disease progression. Increasing concerns regarding antibiotic resistance and the adverse effects associated with conventional antiseptics have encouraged the exploration of safe, affordable, and naturally derived antimicrobial alternatives. The present in vitro study evaluated the antibacterial efficacy of potassium aluminium sulphate (potash alum) against P. gingivalis (ATCC 33277) and determined its minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). The MIC was assessed using a broth microdilution technique adapted from the Clinical and Laboratory Standards Institute (CLSI) M11 guidelines. Serial two‑fold dilutions of potash alum ranging from 100 to 1.56 mg/ml were prepared in supplemented Brain Heart Infusion broth, and bacterial growth was evaluated visually based on turbidity and spectrophotometrically using OD600 measurements. The MBC was determined by sub‑culturing non‑turbid wells onto Brucella blood agar supplemented with hemin and vitamin K1 (BAPHK), followed by anaerobic incubation at 37˚C for 48‑72 h. Potash alum demonstrated concentration‑dependent antibacterial activity, with an MIC of 12.5 mg/ml (1.25%), exhibiting the complete inhibition of visible growth and a markedly reduced OD600 value compared with the positive control. The MBC was identified at 50 mg/ml (5.0%), at which no colonies were detected, corresponding to a reduction of ≥99.9% in viable bacteria. One‑way ANOVA followed by Tukey's HSD post‑hoc test demonstrated statistically significant differences in OD600 values among the treatment groups (F=338.65, P<0.001). On the whole, these findings indicate that potash alum exhibits measurable inhibitory and bactericidal activity against P. gingivalis in vitro and may have potential as an adjunctive antimicrobial agent in periodontal therapy. However, further studies evaluating antibiofilm activity, cytotoxicity, biocompatibility, and clinical efficacy are warranted.
No takes yet. Share an insight, caveat, or question.
Nisha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: